Policy changes Backwork has recorded, newest first. The most recent change on record is from October 24, 2026. Changes appear here after Backwork reviews and applies a refresh, so this page can trail the payers’ own sites.
Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
86,510 on record
| Recorded | Payer | Policy | Change |
|---|---|---|---|
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Axatilimab (e.g., Niktimvo) | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Avelumab (e.g., Bavencio) | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Avalglucosidase alfa-ngpt (e.g., Nexviazyme) | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Avacincaptad pegol (e.g., Izervay) | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Autonomic Nervous System Testing | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Automated Whole Breast Ultrasound | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Autologous Stem-cell Therapy to Treat Peripheral Arterial Disease | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Autologous Chondrocyte Implantation for Focal Articular Cartilage Lesions | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Autism Spectrum Disorder, Other Interventions | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Autism Spectrum Disorder Adaptive Behavioral Analysis | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Auditory Evoked Potential | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Auditory Brain Stem Implant | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Atidarsagene autotemcel (e.g., Lenmeldy) | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Atezolizumab and Atezolizumab with Hyaluronidase (e.g., Tecentriq and Tecentriq Hybreza) | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Asparagine Specific Enzymes (e.g., Rylaze, Asparlas, Oncaspar) | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Asfotase alfa (e.g. Strensiq) | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Artificial Heart, Total | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Arthroereisis for Pes Planus (Flat Feet) (Subtalar stabilization) | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Aqueous Shunts and Devices for Glaucoma | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Apomorphine (e.g., Onapgo) | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Apheresis, Therapeutic (Plasma Exchange Transfusion) | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Accelerated Breast Irradiation and Brachytherapy for Breast and Gynecological Cancers | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Antigen Leukocyte Antibody Test (ALCAT) | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Anti-tissue Factor Pathway Inhibitors [Marstacimab-hncq (e.g., Hympavzi) and Concizumab-mtci (e.g., Alhemo)] | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Annuloplasty, Percutaneous Intradiscal: Electrothermal (IDET), Radiofrequency (PIRFT) or Biacuplasty | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Anifrolumab-fnia (e.g., Saphnelo) | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Angioplasty/Stenting, Percutaneous, Carotid Artery | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Amniotic Membrane and Amniotic Fluid Injections | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Amniocentesis and/or Chorionic Villus Sampling to Detect Fetal Hereditary or Chromosomal Abnormalities | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Amivantamab-vmjw (e.g., Rybrevant) | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Ambulatory Blood Pressure Monitoring | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Alpha-1 Proteinase Inhibitor Therapy (e.g., Aralast, Glassia, Prolastin, and Zemaira) | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Allograft Injection for Degenerative Disc Disease | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Allogeneic processed thymus tissue-agdc (e.g., Rethymic) | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Allogeneic Donor Leukocyte Infusion | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Allergy Immunotherapy | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Allergen Specific In Vitro Testing (e.g., IgE, IgG) | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Alglucosidase alfa (e.g., Lumizyme) | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Alemtuzumab (e.g., Lemtrada) | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Alcohol Injections for Treatment of Peripheral Neuromas | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Airway Clearance Devices | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Air Ambulance | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Afamitresgene autoleucel (e.g., Tecelra) | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Afamelanotide (e.g., Scenesse) | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Tisagenlecleucel (e.g., Kymriah) | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Ado-Trastuzumab Emtansine (e.g., Kadcyla (Trastuzumab-DM1)) for Treatment of HER-2 Positive Malignancies | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Adipose-Derived Stem Cells in Autologous Fat Grafting to the Breast | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | ADAMTS13, recombinant-krhn (e.g., Adzynma) | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Ablative Procedures for Benign Prostatic Hyperplasia (BPH) and Minimally Invasive Benign Prostatic Hyperplasia Treatments | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Ablation Therapy for Atrial Fibrillation (Pulmonary Venous Isolation, Radiofrequency, Cryoablation, Pulsed Field Ablation, AV Node Ablation) | New policy |